These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 33076914)

  • 1. Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study.
    Veit T; Barnikel M; Crispin A; Kneidinger N; Ceelen F; Arnold P; Munker D; Schmitzer M; Barton J; Schiopu S; Schiller HB; Frankenberger M; Milger K; Behr J; Neurohr C; Leuschner G
    Respir Res; 2020 Oct; 21(1):270. PubMed ID: 33076914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study.
    Wijsenbeek MS; Bendstrup E; Valenzuela C; Henry MT; Moor CC; Jouneau S; Fois AG; Moran-Mendoza O; Anees S; Mirt M; Bengus M; Gilberg F; Kirchgaessler KU; Vancheri C
    Adv Ther; 2021 Jul; 38(7):4040-4056. PubMed ID: 34117601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
    Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
    Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
    Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis.
    Russell AM; Adamali H; Molyneaux PL; Lukey PT; Marshall RP; Renzoni EA; Wells AU; Maher TM
    Am J Respir Crit Care Med; 2016 Oct; 194(8):989-997. PubMed ID: 27089018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung disease.
    Maher TM; Schiffman C; Kreuter M; Moor CC; Nathan SD; Axmann J; Belloni P; Bengus M; Gilberg F; Kirchgaessler KU; Wijsenbeek MS
    Respir Res; 2022 Nov; 23(1):307. PubMed ID: 36369156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility and acceptability of remotely monitoring spirometry and pulse oximetry as part of interstitial lung disease clinical care: a single arm observational study.
    Barth S; Edwards C; Saini G; Haider Y; Williams NP; Storrar W; Jenkins G; Stewart I; Wickremasinghe M
    Respir Res; 2024 Apr; 25(1):162. PubMed ID: 38622608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using forced vital capacity (FVC) in the clinic to monitor patients with idiopathic pulmonary fibrosis (IPF): pros and cons.
    Nathan SD; Wanger J; Zibrak JD; Wencel ML; Burg C; Stauffer JL
    Expert Rev Respir Med; 2021 Feb; 15(2):175-181. PubMed ID: 32985286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease trajectories in interstitial lung diseases - data from the EXCITING-ILD registry.
    Buschulte K; Kabitz HJ; Hagmeyer L; Hammerl P; Esselmann A; Wiederhold C; Skowasch D; Stolpe C; Joest M; Veitshans S; Höffgen M; Maqhuzu P; Schwarzkopf L; Hellmann A; Pfeifer M; Behr J; Karpavicius R; Günther A; Polke M; Höger P; Somogyi V; Lederer C; Markart P; Kreuter M
    Respir Res; 2024 Mar; 25(1):113. PubMed ID: 38448953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry.
    Hambly N; Farooqi MM; Dvorkin-Gheva A; Donohoe K; Garlick K; Scallan C; Chong SG; MacIsaac S; Assayag D; Johannson KA; Fell CD; Marcoux V; Manganas H; Morisset J; Comes A; Fisher JH; Shapera S; Gershon AS; To T; Wong AW; Sadatsafavi M; Wilcox PG; Halayko AJ; Khalil N; Cox G; Richeldi L; Ryerson CJ; Kolb M
    Eur Respir J; 2022 Oct; 60(4):. PubMed ID: 35273032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis.
    Reichmann WM; Yu YF; Macaulay D; Wu EQ; Nathan SD
    BMC Pulm Med; 2015 Dec; 15():167. PubMed ID: 26714746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database.
    Hoffmann-Vold AM; Allanore Y; Alves M; Brunborg C; Airó P; Ananieva LP; Czirják L; Guiducci S; Hachulla E; Li M; Mihai C; Riemekasten G; Sfikakis PP; Kowal-Bielecka O; Riccardi A; Distler O;
    Ann Rheum Dis; 2021 Feb; 80(2):219-227. PubMed ID: 32988845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of online home spirometry in systemic sclerosis-associated interstitial lung disease: a pilot study.
    Moor CC; van Leuven SI; Wijsenbeek MS; Vonk MC
    Rheumatology (Oxford); 2021 May; 60(5):2467-2471. PubMed ID: 33212511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Characteristics and clinical significance of pulmonary function test and KL-6 in ASSD-ILD and IPF].
    Sun D; Cheng Z; Jiang TC; Li PF; Jia LQ; Wang TT; Zheng CP; Li Y; Duo MJ
    Zhonghua Yi Xue Za Zhi; 2020 Mar; 100(10):748-752. PubMed ID: 32192286
    [No Abstract]   [Full Text] [Related]  

  • 15. A simple dyspnoea scale as part of the assessment to predict outcome across chronic interstitial lung disease.
    Khadawardi H; Mura M
    Respirology; 2017 Apr; 22(3):501-507. PubMed ID: 27862639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study).
    Nasser M; Larrieu S; Si-Mohamed S; Ahmad K; Boussel L; Brevet M; Chalabreysse L; Fabre C; Marque S; Revel D; Thivolet-Bejui F; Traclet J; Zeghmar S; Maucort-Boulch D; Cottin V
    Eur Respir J; 2021 Feb; 57(2):. PubMed ID: 32943410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
    Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reticulation pattern without honeycombing on high-resolution CT is associated with the risk of disease progression in interstitial lung diseases.
    Mononen M; Saari E; Hasala H; Kettunen HP; Suoranta S; Nurmi H; Kärkkäinen M; Selander T; Randell J; Laurikka J; Uibu T; Koskela H; Kaarteenaho R; Purokivi M
    BMC Pulm Med; 2022 Aug; 22(1):313. PubMed ID: 35965320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progressive fibrosing interstitial lung disease: prevalence and clinical outcome.
    Kwon BS; Choe J; Chae EJ; Hwang HS; Kim YG; Song JW
    Respir Res; 2021 Oct; 22(1):282. PubMed ID: 34719401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of gastroesophageal factors and worsening of forced vital capacity in systemic sclerosis.
    Zhang XJ; Bonner A; Hudson M; ; Baron M; Pope J
    J Rheumatol; 2013 Jun; 40(6):850-8. PubMed ID: 23547215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.